Actemra in giant cell arteritis, a form of vasculitis: FDA grants Breakthrough Therapy Designation
The FDA ( Food and Drug Administration ) has granted Breakthrough Therapy Designation status to Actemra ( Tocilizumab; in Europe: RoActemra ) for giant cell arteritis ( GCA ), a chronic, potentially l ...
read article